Analysts say that after a roughly two-year turnaround the company's retail pharmacy business and other units may be strong enough to stand on their own.
The move would reverse the company's $78 billion acquisition of Aetna, and dismantle the vertically integrated healthcare conglomerate it created in 2018.
Genmab's shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.